Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/24/2025

Antibiotic Treatment for Urinary Tract Infections in Men

First-Line Antibiotic Regimen

  • The European Urology Association recommends trimethoprim-sulfamethoxazole 160/800 mg twice daily for 7 days as the first-line treatment for men with urinary tract infections 1, 2, 3
  • For uncomplicated UTI, the treatment duration with trimethoprim-sulfamethoxazole is 7 days 1, 2, 3
  • When prostatitis cannot be excluded, the treatment duration with trimethoprim-sulfamethoxazole is 14 days 4

Alternative Antibiotic Options

  • The European Urology Association recommends fluoroquinolones, such as ciprofloxacin or levofloxacin, as alternative treatments when trimethoprim-sulfamethoxazole cannot be used or resistance is suspected 1, 2, 3
  • Ciprofloxacin can be used at a dose of 500 mg twice daily for 7-14 days 4
  • Levofloxacin can be used at a dose of 750 mg once daily for 7-14 days 4

Critical Clinical Considerations

  • Obtaining a urine culture before initiating antibiotics is crucial to guide potential adjustments based on susceptibility results 4
  • Common uropathogens in men include E. coli, Proteus species, Klebsiella species, Pseudomonas species, and Enterococcus species 4
  • The treatment duration can be decided based on the patient's response, with 7 days being acceptable if the patient becomes afebrile within 48 hours and shows clear clinical improvement, and 14 days being required when prostatitis cannot be excluded 4

Common Pitfalls to Avoid

  • Fluoroquinolones should not be used as first-line empiric therapy when other effective options like trimethoprim-sulfamethoxazole are available 4
  • Treating for only 3-5 days is not recommended for men, as they require a minimum of 7 days due to the complicated nature of male UTIs and potential prostatic involvement 1, 2, 3, 4
  • Skipping urine culture in men can complicate management if initial empiric therapy fails and susceptibility data is lacking 4